Eli Lilly has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization (MA) for its ulcerative colitis treatment, Mirikizumab.
Takeda has partnered with Portal Instruments to develop a needle-free drug delivery device for biologic medicines, starting with the former’s Entyvio (vedolizumab).
The Switzerland-headquartered contract research organization (CRO) has opened offices in Taiwan following a string of investments in the Asia Pacific region.
Shire says it will appeal a decision invalidating a patent surrounding the controlled-release composition of its ulcerative colitis drug Lialda (mesalazine).
Celltrion’s CT-P13 has been declared “highly similar” in safety and efficacy to J&J’s Remicade, and could be recommended for approval by a US FDA committee today.
US researchers have found that using an ultrasound probe increases small molecule delivery through the intestinal tract of animal models and could help deliver drugs in human.
Celgene has shelled out $7.2bn (€6.6bn) to acquire Receptos which is developing an oral lymphocyte trafficking agent for multiple sclerosis and inflammatory bowel disorder.
Encap Drug Delivery now offers a ‘feasibility package’ to assess the potential of its Phoral coating technology as a vehicle for therapy in colonic diseases.
CMO Encap has expanded its colonic delivery offering and is combining the technology with liquid dosage forms to provide clients with a way to administer a wide range of therapeutics to the region.
Prometheus Laboratories has initiated US Phase II trials of
Colal-Pred, a treatment for ulcerative colitis which uses Alizyme's
drug delivery technology to provide therapeutics solely to the
colon.
SynCo Bio Partners has completed production of AG011 for ActoGenIX,
enabling the latter firm to begin examining it in patients
suffering from ulcerative colitis (UC).
PDL Biopharma has seen a week of drama after announcing a
restructure that left its key investor calling for the company
chairman to resign, a week after its CEO also decided to step
down after similar pressure.
Italian firm Cosmo Pharmaceuticals has announced positive
preliminary results from trials testing out a new formulation of an
antibioticfor traveller's diarrhoea that makes use of the
company's innovative MMX technology.
Cosmo Pharmaceuticals is cementing its place in the inflammatory
bowel disease (IBD) drug market with eight new drugs in various
stages of reformulation using the company's cutting-edge MMX
technology, the company announced recently.
Pharma company Shire has agreed with European regulators on
labelling information for its ulcerative colitis drug Mezavant, a
further step in the firm's ambition to capture more of the $1.6bn
(€1.2bn) mesalazine market through...
Merck and Chi-Med have announced the start of their collaboration,
which aims to discover novel small molecule anti-cancer drugs
derived from natural products that modulate oncological pathways.
Kemwell has sealed the deal on the purchase of Pfizer's Swedish
manufacturing plant and at the same time secured a long-term
contract manufacturing agreement with the drug giant.
Researchers have identified a protein that is thought to defend the
intestinal against microbial invaders offering new insights into
how the intestine fends off pathogens and potentially leading to
new inflammatory bowel disease medications.
The gastrointestinal (GI) market is one of the largest in the
pharma industry and continues to attract a high level of R&D
investment, however, the market has recently entered a crucial
phase, with mounting commercial pressures...
Ferring has opened a new production plant in Switzerland as it
tries to cut costs by centralising its manufacturing network.
In-PharmaTechnologist.com visited the site to see how the drugmaker
is streamlining its supply chain.
In its first venture outside the subcontinent, though certainly not
the last of its kind for India pharma companies, contract
pharmaceuticals manufacturer Kemwell has bought for an undisclosed
sum Pfizer's production plant in...
Nucryst Pharmaceuticals has been granted a new patent that covers
the company's proprietary nanocrystalline silver for use in the
treatment of acne. This latest addition strengthens the company's
patent portfolio, which...
Specialty pharmaceutical firm Shire has filed for approval to
European Regulatory Agencies of SPD476, an ulcerative colitis drug
which uses Cosmo's cutting-edge MMX multi matrix system, promising
to give the company the upper...
Medarex has announced the initiation of a phase I clinical trial of
its human monoclonal antibody for the treatment of ulcerative
colitis after the FDA granted the company an Investigational New
Drug (IND) application.
Serono has licensed rights to a drug that takes a novel approach to
the treatment of ulcerative colitis, a common disease that is
asociated with debilitating symptoms, including cancer, but remains
poorly treated with existing drugs.
